RENACIDIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RENACIDIN (RENACIDIN).
Renacidin (citric acid, glucono-delta-lactone, and magnesium carbonate) dissolves struvite calculi by chelating calcium and magnesium ions and by providing a buffered acid environment (pH 3.5-4.0) that enhances solubility of struvite crystals.
| Metabolism | Citric acid is metabolized via the tricarboxylic acid (TCA) cycle; glucono-delta-lactone is hydrolyzed to gluconic acid and further metabolized; magnesium carbonate dissociates to magnesium and carbonate ions, with magnesium excreted renally. |
| Excretion | Renacidin (citric acid, glucono-delta-lactone, and magnesium carbonate) is a urinary tract irrigant. Following irrigation, the components are largely eliminated renally. Minimal systemic absorption occurs; absorbed citrate is metabolized via the Krebs cycle. Excretion is primarily renal (>95% as citrate and metabolites), with <5% fecal. |
| Half-life | Terminal elimination half-life is not clinically applicable due to local action. For absorbed citrate, half-life is approximately 0.5–1 hour in patients with normal renal function. Accumulation may occur in renal impairment. |
| Protein binding | Citrate: <10% bound to plasma proteins (primarily albumin). Magnesium: ~30% bound to albumin. Glucono-delta-lactone: negligible binding. |
| Volume of Distribution | Systemically absorbed citrate: Vd approximately 0.2–0.4 L/kg, distributing primarily in extracellular fluid. Magnesium: Vd ~0.3 L/kg. Clinical significance: low Vd indicates limited tissue distribution; accumulation risk in renal failure. |
| Bioavailability | Not applicable for oral or systemic routes; Renacidin is used exclusively for local bladder irrigation. Systemic absorption is minimal (<1% of dose). |
| Onset of Action | Local irrigation: Onset of dissolution effect is immediate upon contact with calculi; clinical dissolution may begin within hours of irrigation, but optimal effect requires continuous irrigation over several days. |
| Duration of Action | Duration of local action is limited to irrigation period; continuous irrigation is required for sustained dissolution. Residual effect does not persist after irrigation stops. |
Instill 15-30 mL of solution via ureteral catheter for 5-15 minutes; repeat as needed based on stone dissolution. Use only under direct endoscopic visualization.
| Dosage form | SOLUTION |
| Renal impairment | Not applicable; Renacidin is used topically in the urinary tract and systemic absorption is minimal. No dose adjustment for renal impairment. |
| Liver impairment | Not applicable; no systemic absorption. No dose adjustment for hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use is not recommended in pediatric patients. |
| Geriatric use | No specific dose adjustments; use with caution due to potential for electrolyte disturbances, especially in elderly with compromised renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RENACIDIN (RENACIDIN).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Given minimal systemic absorption after intrarenal administration, risk to infant likely low. However, consider alternatives or discontinue breastfeeding if prolonged use. |
| Teratogenic Risk | No human data; animal studies not available. Renacidin is a citric acid-based solution for renal calculi dissolution. Systemic absorption minimal, but avoid during pregnancy unless benefit outweighs potential unknown fetal risks. First trimester: theoretical risk of metabolic disturbances; second and third trimesters: limited data, but cautious use due to possible calcium shifts. |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: Known hypersensitivity to any component, acute or chronic renal failure, severe renal impairment (creatinine clearance <20 mL/min), obstructive uropathy, pyelonephritis, infected urine with urea-splitting organisms.","Relative: Moderate renal impairment (creatinine clearance 20-50 mL/min), electrolyte imbalances (e.g., hypermagnesemia, hyperphosphatemia)."]
| Precautions | ["Elevated serum magnesium and phosphate levels may occur; monitor serum electrolytes, magnesium, and phosphate during therapy.","Risk of acute renal failure and hypermagnesemia; use with caution in patients with renal impairment.","Do not use in patients with pyelonephritis, obstructive uropathy, or compromised renal function.","Irrigation solution only; not for intravenous use."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, potassium, calcium, magnesium, bicarbonate) and acid-base status regularly. Monitor renal function and urine pH. Fetal monitoring as per obstetric indications. |
| Fertility Effects | No known effects on fertility. Renacidin is not systemically absorbed; local action in renal pelvis unlikely to impact reproductive function. |